VERQUVO (vericiguat)

Self Administration – Oral

Diagnosis considered for coverage:
  • Chronic Heart Failure - indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics in adults with symptomatic chronic HF and ejection fraction less than 45%.
Coverage Criteria:
  • For diagnosis of Chronic Heart Failure:
  • Dose does not exceed 10 mg once daily, and
  • Prescribed by or in consultation with a cardiologist, and
  • Patient has an ejection fraction less than 45 percent; and
  • Patient has New York Heart Association (NYHA) Class II, III, IV symptoms; and
  • One of the following:
    • Patient was hospitalized for heart failure within the last 6 months, or
    • Patient used outpatient intravenous (IV) diuretics (e.g., bumetanide, furosemide) for heart failure within the last 3 months.
  • Trial and failure, contraindication, or intolerance to BOTH of the following:
    • Beta-blocker (e.g., bisoprolol, carvedilol)
    • One of the following:
      • Angiotensin converting enzyme (ACE) inhibitor (e.g., captopril, enalapril), or
      • Angiotensin II receptor blocker (ARB) (e.g., candesartan, valsartan), or
      • Angiotensin receptor-neprilysin inhibitor (ARNI) [e.g., Entresto (sacubitril and valsartan)].
Reauthorization Criteria:

For diagnosis of Chronic Heart Failure:

  • Dose does not exceed 10 mg once daily, and
  • Documentation of a positive clinical response to therapy.
Coverage Duration:
  • Initial: up to 12 months.
  • Reauthorization: up to 12 months.
Additional Information:
  • The recommended starting dose of Verquvo is 2.5 mg orally once daily with food. Double the dose of Verquvo approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the patient.
Policy Updates:
  • 06/15/2021 – New policy approved by P&T
References:
  • Armstrong PW, Pieske B, Anstrom KJ, et al; VICTORIA Study Group. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020 May 14;382(20):1883-1893. doi: 10.1056/NEJMoa1915928.
  • Food and Drug Administration. Verquvo integrated review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214377Orig1s000IntegratedR.pdf. February 17, 2021. Accessed March 26, 2021.
  • Hollenberg SM, Warner Stevenson L, Ahmad T, et al. 2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2019 Oct 15;74(15):1966-2011. doi: 10.1016/j.jacc.2019.08.001.
  • Maddox TM, Januzzi JL Jr, Allen LA, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021 Feb 16;77(6):772-810. doi: 10.1016/j.jacc.2020.11.022.
  • Verquvo [package insert], Whitehouse Station, NJ: Merck & Co., Inc.; January 2021.
  • Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2013 Oct 15;62(16):e147-239.
  • Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Journal of the American College of Cardiology. 2017 Aug 8;70(6):776-803.

 

 

 

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone